DOP51 De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation

Pepijn W. A. Thomas(Radboud University Nijmegen), Frank Hoentjen(Radboud University Nijmegen), Maarten te Groen(Radboud University Nijmegen), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Lisa Smits(Radboud University Nijmegen), M. Russel(Medisch Spectrum Twente), Jeroen M. Jansen(OLVG), Robert West(The Behaviouralist (United Kingdom))
Journal of Crohn s and Colitis
May 1, 2021
10.1093/ecco-jcc/jjab073.090
Cited by 0

Related Papers

Cassini Observes the Active South Pole of Enceladus
|Science|2006|1.2k
Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
|The Lancet|2016|1.2k
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis
|New England Journal of Medicine|2021|269
IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes
|Nature Communications|2018|252